[go: up one dir, main page]

BRPI0414722A - meios sem produto animal e processos para obtenção de uma toxina botulìnica - Google Patents

meios sem produto animal e processos para obtenção de uma toxina botulìnica

Info

Publication number
BRPI0414722A
BRPI0414722A BRPI0414722-7A BRPI0414722A BRPI0414722A BR PI0414722 A BRPI0414722 A BR PI0414722A BR PI0414722 A BRPI0414722 A BR PI0414722A BR PI0414722 A BRPI0414722 A BR PI0414722A
Authority
BR
Brazil
Prior art keywords
obtaining
processes
toxin
animal
botulically
Prior art date
Application number
BRPI0414722-7A
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34376493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0414722A publication Critical patent/BRPI0414722A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MEIOS SEM PRODUTO ANIMAL E PROCESSOS PARA OBTENçãO DE UMA TOXINA BOTULìNICA". A presente invenção refere-se a meio e processos para a fermentação de Clostridium botulinum e obtenção de uma toxina botulínica para uso em formulação de composições farmacêuticas de toxina botulínica. Os meios de crescimento podem conter níveis significativamente reduzidos de subprodutos de carne ou de laticínios usando produtos à base não-animais para substituir os produtos derivados de animal. Preferencialmente, os meio usados são substancialmente livres de produtos derivados de animal.
BRPI0414722-7A 2003-09-25 2004-08-25 meios sem produto animal e processos para obtenção de uma toxina botulìnica BRPI0414722A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/672,876 US7148041B2 (en) 2003-09-25 2003-09-25 Animal product free media and processes for obtaining a botulinum toxin
PCT/US2004/027775 WO2005035749A2 (en) 2003-09-25 2004-08-25 Animal product free media and processes for obtaining a botulinum toxin

Publications (1)

Publication Number Publication Date
BRPI0414722A true BRPI0414722A (pt) 2006-11-21

Family

ID=34376493

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414722-7A BRPI0414722A (pt) 2003-09-25 2004-08-25 meios sem produto animal e processos para obtenção de uma toxina botulìnica

Country Status (18)

Country Link
US (4) US7148041B2 (pt)
EP (2) EP2177607A1 (pt)
JP (3) JP2007506427A (pt)
KR (1) KR101100567B1 (pt)
CN (1) CN1856569B (pt)
AR (1) AR045813A1 (pt)
AT (1) ATE469215T1 (pt)
AU (1) AU2004280450B2 (pt)
BR (1) BRPI0414722A (pt)
CA (1) CA2540072A1 (pt)
DE (1) DE602004027393D1 (pt)
DK (1) DK1664292T3 (pt)
ES (1) ES2344843T3 (pt)
MX (1) MXPA06003029A (pt)
NZ (1) NZ545503A (pt)
PL (1) PL1664292T3 (pt)
TW (1) TWI294914B (pt)
WO (1) WO2005035749A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
EP1853622B1 (en) * 2005-03-03 2014-07-16 Allergan, Inc. Processes for obtaining a clostridial toxin
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
PT1893033E (pt) * 2006-07-07 2008-12-02 Alpro Nv Método para preparar um análogo de um produto lácteo
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
ES2615281T3 (es) 2009-06-24 2017-06-06 Charles N.S. Soparkar Suplementación con cinc para aumentar la capacidad de respuesta al tratamiento con metaloproteasa
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2275527A1 (en) * 2009-07-17 2011-01-19 ActoGeniX NV Animal component-free culture medium for bacterial fermentation
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
PL3372239T3 (pl) 2012-05-30 2021-05-04 President And Fellows Of Harvard College Zaprojektowana neurotoksyna botulinowa
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
ES2895853T3 (es) 2015-03-26 2022-02-22 Harvard College Neurotoxina botulínica modificada
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723168B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101729251B1 (ko) 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
DK3292134T3 (da) 2015-05-06 2020-11-23 Univ Wageningen Metode til dyrkning af akkermansia
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
KR102567311B1 (ko) 2016-05-16 2023-08-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 보툴리눔 신경독소의 정제 및 활성화 방법
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
RS59600B2 (sr) 2016-09-13 2022-10-31 Allergan Inc Stabilizovane kompozicije neproteinskog toksina klostridije
KR102209159B1 (ko) 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102197224B1 (ko) 2019-03-29 2020-12-31 (주)제테마 배지 조성물
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
KR102750531B1 (ko) 2022-09-23 2025-01-09 (주)제테마 보툴리눔 독소 생산성을 증가시키는 방법
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720447A2 (de) * 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) * 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
ES2293681T3 (es) 1997-05-28 2008-03-16 Novartis Vaccines And Diagnostics S.R.L. Medio de cultivo con extracto de soja como fuente de aminoacidos pero sin complejos proteinicos de origen animal.
US6171605B1 (en) 1999-07-08 2001-01-09 Color Access, Inc. Self tanning compositions containing DHA and propolis extract
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
AU1571801A (en) 1999-11-12 2001-05-30 Eli Lilly And Company Improved fermentation process
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ES2237551T3 (es) * 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7452687B2 (en) * 2002-03-29 2008-11-18 Asahi Kasei Pharma Corporation Method of detecting mild impaired glucose tolerance or insulin secretory defect
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
CA2472611C (en) 2003-07-02 2009-09-15 Filtertek Inc. Multiple retainer bridge
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
EP1853622B1 (en) 2005-03-03 2014-07-16 Allergan, Inc. Processes for obtaining a clostridial toxin

Also Published As

Publication number Publication date
EP2177607A1 (en) 2010-04-21
ES2344843T3 (es) 2010-09-08
US7189541B2 (en) 2007-03-13
JP2012070759A (ja) 2012-04-12
AU2004280450A1 (en) 2005-04-21
CA2540072A1 (en) 2005-04-21
WO2005035749A2 (en) 2005-04-21
US20060240514A1 (en) 2006-10-26
US7148041B2 (en) 2006-12-12
US20090022763A1 (en) 2009-01-22
CN1856569A (zh) 2006-11-01
AR045813A1 (es) 2005-11-16
US8008044B2 (en) 2011-08-30
WO2005035749A3 (en) 2005-06-02
AU2004280450B2 (en) 2009-02-05
KR101100567B1 (ko) 2011-12-29
EP1664292A2 (en) 2006-06-07
JP2015051019A (ja) 2015-03-19
CN1856569B (zh) 2010-12-01
MXPA06003029A (es) 2006-06-23
JP2007506427A (ja) 2007-03-22
EP1664292B1 (en) 2010-05-26
US20050069562A1 (en) 2005-03-31
DE602004027393D1 (de) 2010-07-08
PL1664292T3 (pl) 2010-10-29
ATE469215T1 (de) 2010-06-15
TWI294914B (en) 2008-03-21
US20060228777A1 (en) 2006-10-12
TW200516142A (en) 2005-05-16
US7445914B2 (en) 2008-11-04
KR20060102330A (ko) 2006-09-27
NZ545503A (en) 2009-04-30
DK1664292T3 (da) 2010-08-30

Similar Documents

Publication Publication Date Title
BRPI0414722A (pt) meios sem produto animal e processos para obtenção de uma toxina botulìnica
BRPI0508374A (pt) meios para bactéria clostrìdio e processo para obtenção de uma toxina clostrìdica
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
BRPI0412978A (pt) cultura biologicamente pura de grupo bacteriano, co-cultura bacteriana, composição terapêutica, aditivo ou suplemento alimentar, gênero alimentìcio, método para tratar ou prevenir desordem e artigo de manufatura
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
AU2003212265A1 (en) Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
GB201018518D0 (en) Novel endolysin
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
NO20062878L (no) Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
BRPI0406037A (pt) Produto de carne ou análogo de carne contendo soja, e, método para preparar o mesmo
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
EP1620112A4 (en) DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
BRPI0406125A (pt) produto de queijo contendo soja, e, método para preparar o mesmo
BR0110394A (pt) Proteìna anti-congelamento, sequência nucleica, vetor, método para produzir uma proteìna anti-congelamento, organismo geneticamente modificado, extrato contendo proteìna, e, produto alimentìcio
BRPI0409521A (pt) uso do pentapeptìdeo iiaek, do pentapeptìdeo ipavf e/ou do hexapeptìdeo ipavfk, produto alimentìcio e processo para a preparação de um produto alimentìcio

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/64 , C12N 1/20 , C12P 21/02

Ipc: C12P 21/02 (2006.01), C12N 1/20 (2006.01), C12N 9/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]